Skip to main content
. 2024 Dec 6;28(3):111536. doi: 10.1016/j.isci.2024.111536

Figure 4.

Figure 4

IN10018 reduces CAFs and enhances Trastuzumab uptake in tumors, thereby improving the anticancer efficacy of Enhertu

(A) The schematic figure for the animal experiment with NIH/3T3/NCI-N87 co-inoculation model.

(B) The representative images of FAP staining for the tumors of the NIH/3T3-NCI-N87 co-inoculation model.

(C) The percentage of FAP-positive area of the tumors from NIH/3T3-NCI-N87 co-inoculation model.

(D–G) The red fluorescence imaging for the NIH/3T3-NCI-N87 co-inoculation model treated with IN10018 and Trastuzumab Cy5.5. The mice were treated with 25 mg/kg IN10018 for 10 days and then dosed with one injection of Trastuzumab Cy5.5 (3 mg/kg). Six hours (D and E) and 48 h (F and G) later, the red fluorescence imaging was performed for the mice to check with the infiltrated amount of the antibody within tumors.

(H–I) The tumor growth curves and body weight changes of the efficacy study with NIH/3T3-NCI-N87 co-inoculation model. The animal model was treated with 25 mg/kg IN10018 once daily per oral and 3 mg/kg Enhertu twice on day 9 and day 28. Data represent mean ± SEM. The unpaired student’s t test was used for the statistical analysis. NS, non-significant; ∗p < 0.05, ∗∗p < 0.01. Scale bar: 200 μm.